Evidence map›Paper›PMID 32104494›Full record

ArticleAsian journal of pharmaceutical sciences2019

Piperacillin enhances the inhibitory effect of tazobactam on β-lactamase through inhibition of organic anion transporter 1/3 in rats.

Shilei Yang, Zhihao Liu, Changyuan Wang, Shijie Wen, Qiang Meng, Xiaokui Huo, Huijun Sun, Xiaodong Ma, Jinyong Peng, Zhonggui He and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shilei YangDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Zhihao LiuDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Changyuan WangDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Shijie WenDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Qiang MengDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Xiaokui HuoDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Huijun SunDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Xiaodong MaDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Jinyong PengDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Zhonggui HeWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Kexin LiuDepartment of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Dalian Medical University · CNShenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the mechanism of the pharmacokinetic interaction between piperacillin and tazobactam, renal excretion and pharmacokinetic studies of piperacillin/tazobactam were investigated in normal and bacteremia rats. A bacteremia model was established to investigate the pharmacokinetic properties of piperacillin and tazobactam under different conditions. Renal slices were taken to examine the uptake of piperacillin and tazobactam. Pharmacokinetic studies of β-lactamase in rats were performed to study the contribution of rOat1/3 to the inhibition of tazobactam on β-lactamase. The

Indexed as

Drug-drug interactionOrganic anion transporterPiperacillinTazobactam

Identifiers

PMID32104494
PMCPMC7032209
OpenAlexW2904817009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.